Introduction: The effects of edaravone against pentylenetetrazole (PTZ)-induced
| INTRODUC TI ON
Edaravone is a well-known commercial drug used in the treatment of strokes and amyotrophic lateral sclerosis (ALS) (Miyaji et al., 2015) .
Antioxidant and free radical scavenging activities of edaravone have been reported in patients with ALS (Petrov, Mansfield, Moussy, & Hermine, 2017) . Researchers have reported that edaravone exhibits a neuronal protective effect by reducing brain damage in a model of acute ischemia (Watanabe, Tanaka, Watanabe, Takamatsu, & Tobe, 2004) . Edaravone has been reported to be active against lipid peroxidation and to exhibit free radical quenching activity (Watanabe, Yuki, Egawa, & Nishi, 1994; Yoshida, Yanai, Namiki, & Fukatsu-Sasaki, 2006 ). Cheng and Zhang (2014) reported that edaravone treatment reduced apoptosis in the hippocampus following pentylenetetrazole (PTZ)-induced seizures.
Cyclooxygenases (COXs) are enzymes involved in the conversion of arachidonic acid to prostaglandins, which play a major role in the inflammatory reaction (Simmons, Botting, & Hla, 2004) .
Cyclooxygenases exist in two forms, COX-I and COX-II, in different cell types. COX-II is predominantly found in the central nervous system (CNS) and is induced in areas of inflammation following injury (Choi, Aid, & Bosetti, 2009 ). Choi et al. (2009) reported that COX-II is primarily expressed in the hippocampus and cerebral cortex and is involved in seizure onset. Chen, Magee, and Bazan (2002) reported that COX-II regulates prolonged synaptic plasticity and cell membrane excitability, indicating the importance of COX-II in convulsion.
Nitric oxide (NO) is a well-known neurotransmitter produced from arginine by nitric oxide synthase (NOS; Zhou & Zhu, 2009) . NO is known to increase PTZ-induced seizures (Riazi et al., 2006) . The simultaneous synthesis of prostaglandins and NO has been reported in various tissues, as well as their putative roles in inflammatory reactions, indicating a possible interaction between prostaglandins and NO (Mollace, Muscoli, Masini, Cuzzocrea, & Salvemini, 2005) .
To date, no study has investigated the effects of edaravone on the levels of COX-II and NO in a rat PTZ-induced seizure model.
| MATERIAL S AND ME THODS
Twenty-four male rats (Albino, Wistar strain, 200-220 g) were obtained from the animal facility of the Key Laboratory of Neurology of Hebei Province, the Second Hospital of Hebei Medical University (Shijiazhuang, Hebei, PR China). The rats were distributed into four homogeneous groups, with six rats in each group. Water and food were provided ad libitum, and rats were kept in cages with standard light and dark period. All experimental procedures involving rats were monitored and approved by the Second Hospital of Hebei Medical University (Shijiazhuang, Hebei, PR China).
| Treatment
The experimental groups were as follows: sham, control, 5 mg/kg edaravone, and 10 mg/kg edaravone. PTZ (Sigma-Aldrich Inc., China) was dissolved in normal saline (0.9%) and administered intraperitoneally (Ebrahimzadeh Bideskan et al., 2011) . PTZ (90 mg/kg body weight) was administered to rats in control, 5 mg/kg edaravone, and 10 mg/kg edaravone groups. Saline was given to the sham and control groups instead of edaravone. Doses were administered orally for 15 consecutive days.
| Behavioral assessment
Following administration of PTZ, rats were kept in a Plexiglas chamber (30 × 30 × 30 cm) and observed for 1 hr. Generalized tonicclonic seizure (GTCS) and latency to the first minimal clonic seizure (MCS), the incidence of GTCS and MCS, and mortality rate were calculated as criteria for the behavioral response to PTZ administration (Ebrahimzadeh Bideskan et al., 2011; Hosseini, Sadeghnia, Salehabadi, Alavi, & Gorji, 2009 ).
| Mortality rate
Higher mortality rate was observed in control rats (70%-80%). The administration of edaravone (5 mg/kg) slightly reduced mortality rate (15%), while administration of edaravone (10 mg/kg) significantly reduced (27%) compared to their respective controls (data not shown).
| Biochemical markers
Catalase activity was determined by the addition of 500 µl of phosphate buffer, 500 µl of tissue homogenate, 500 µl of H 2 O 2 , and 500 µl of TiOSO 4 to the reaction tube. The absorbance was measured at 420 nm (Feuers, Weindruch, Leakey, Duffy, & Hart, 1997) .
Superoxide dismutase (SOD) activity was determined by the addition of 0.1 ml of tissue homogenate, 1.2 ml of sodium phosphate buffer, 0.3 ml of nitro blue tetrazolium, and 0.2 ml of NADH. The absorbance was measured at 560 nm (Feuers et al., 1997) . Glutathione peroxidase (Gpx) activity in tissue homogenate was determined by measuring the absorbance at 340 nm (Baydas et al., 2002) . Reduced glutathione (GSH) levels in the tissue homogenate were determined based on Ellman's reaction. The final product was measured by the absorbance at 412 nm (Kaddour et al., 2016) . The malondialdehyde (MDA) content was measured as an index of lipid peroxidation in the tissue homogenate by measuring thiobarbituric acid reactive species (TBARS). The resultant final product was measured the absorbance at 534 nm (Power & Blumbergs, 2009) . Total thiol content in the tissue homogenate was determined according to the previously reported method. Briefly, tissue homogenate and colorimetric probe were added to the 96-well plates. The probe reacts with sulfhydryl to release a chromophore, and final the absorbance was measured at 450 nm (Khodabandehloo et al., 2013) .
| Apoptosis assay
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and staining were performed in hippocampal sections as previously described. Hippocampal tissues were excised and perfused in normal saline, and then, hippocampal tissues were fixed in 10% neutral formalin (10%) for 24 hr. Hippocampal sections were dehydrated by graded alcohol and embedded in paraffin film. Then, sections were cut into (4-5 µm) thickness by a rotary microtome. Then, terminal deoxynucleotidyl transferase dUTP nick end label (TUNEL) staining was
performed. An optimal signal-to-background ratio was obtained at 1:4 dilution of the antibody. Then, reaction with 0.05% of 3-3′-diaminobenzidine tetrahydrochloride (DAB) was monitored under the microscope (Graziano, Spoon, Cockrell, Rowse, & Gonzales, 2001 ).
| Determination of NO levels
Nitric oxide (NO) level was determined as in Shaheen et al. (2016) .
Nitrate and nitrite are final products of NO metabolism and these levels used for the quantification of NO. Sum of nitrate and nitrite accounts for the total NO concentration. Griess's reaction was used for the determination of NO level in serum based on the nitrite concentration. In the serum, nitrate was reduced nitrite in the presence of cadmium (Sigma-Aldrich Inc., Shanghai, China). Then, nitrite was converted to nitric acid that reacts with Griess's reagent (Sigma-Aldrich Inc., Shanghai, China) to produce color. Serum level of nitrite was determined by measuring absorbance at 540 nm in a spectrophotometer.
| Real-time polymerase chain reaction (RT-PCR)
Total RNA was isolated from hippocampal tissue homogenate and converted into cDNA using oligo (dT) primers. The cDNA was used for qRT-PCR using primers specific for COX-II (forward: 5′-TGCGATGCTCTTCCGAGCTGTGCT-3′, reverse: 5′-TCAGGAAGTTC CTTATTTCCTTTC-3′) and β-actin (forward: 5′-GATGGCCACGGC TGCTTC-3′, reverse: 5′-TGCCTCAGGGCAGCGGAA-3′) as the internal control. Relative expression ratios were determined according to Langnaese, John, Schweizer, Ebmeyer, and Keilhoff (2008) . TA B L E 1 Effect of edaravone on lipid peroxidation, antioxidant markers, and thiol content in pentylenetetrazoleinduced epilepsy in male albino rats
| Western blot analysis
Proteins in the hippocampal tissue homogenates were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membranes, and incubated with the anti-COX-II primary antibody (ab15191; Abcam) for 12 hr, followed by the horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibody (A0545-1ML; Sigma-Aldrich) for 1 hr. Enhanced chemiluminescence was used to determine protein levels of COX-II (Nie et al., 2017) .
| Immunohistochemistry
Hippocampal tissues were excised and perfused in normal saline, and then, hippocampal tissues were fixed in 10% neutral formalin (10%) for 24 hr. Hippocampal sections were dehydrated by graded alcohol and embedded in paraffin film. Paraffin-embedded hippocampal sections were dewaxed, washed with deionized water, and rinsed with PBS. Hippocampal sections were incubated with goat serum (0.5% bovine serum albumin and 0.1% Tween) for 
| Statistical analysis
Values are given as means with SD. One-way ANOVA (SPSS 17, IBM SPSS Modeler, Hong Kong) was applied for statistical analyses of data, and Tukey's post hoc tests were used for multiple comparisons.
p-values <0.05 were considered statistically significant.
| RE SULTS
In this study, the protective effects of edaravone on PTZ-induced epilepsy in male albino rats were investigated. Seizure incidence, including GTCS and MCS, was directly associated with PTZ administration in rats. Edaravone supplementation substantially increased MCS and GTCS latency in the rats (Figure 1, Apoptosis was drastically increased in PTZ-treated rats compared to the sham group. However, edaravone supplementation reduced apoptosis by more than 50% (Figure 2 , p < 0.05). The NO levels were drastically increased in PTZ-treated rats compared to the sham group. However, the NO level was reduced by 31.9%
and 63.8% following supplementation with 5 and 10 mg/kg eda- 
| D ISCUSS I ON
In this study, the protective effects of edaravone on PTZ-induced epilepsy in male albino rats were investigated. It is believed that PTZ has opposite effect when binds to the GABA-A receptor complex (Squires, Saederup, Crawley, Skolnick, & Paul, 1984) . Antioxidant and free radical scavenging activities of edaravone have been reported in patients with ALS (Petrov et al., 2017) . Edaravone has also been reported to exhibit a neuronal protective effect by reducing brain damage in a model of acute ischemia . Additionally, edaravone has been shown to be active against lipid peroxidation and exhibits free radical quenching activity (Watanabe et al., 1994; Yoshida et al., 2006 reported that COX-II and NO can interact in cardiomyopathy, osteoarthritis, renal perfusion, and angiogenesis (Beierwaltes, 2002; Davel et al., 2002) . Finally, Hughes et al. (1999) demonstrated that NO upregulates COX-II expression. However, to the best of our knowledge, the crosstalk between prostaglandins and NO has not yet been investigated.
| CON CLUS IONS
Edaravone supplementation significantly normalized altered lipid peroxidation and antioxidant biochemical markers. Apoptosis and NO levels were reduced compared to their respective controls.
mRNA and protein expression of COX-II was substantially reduced following edaravone supplementation. Taken together, our results
suggest that edaravone is a potential candidate for the treatment of PTZ-induced epilepsy and functions by downregulating the levels of COX-II and NO.
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